383 related articles for article (PubMed ID: 19643600)
21. Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8.
Häcker S; Dittrich A; Mohr A; Schweitzer T; Rutkowski S; Krauss J; Debatin KM; Fulda S
Oncogene; 2009 Sep; 28(35):3097-110. PubMed ID: 19597472
[TBL] [Abstract][Full Text] [Related]
22. Sensitization of TRAIL-induced apoptosis in human hepatocellular carcinoma HepG2 cells by phytochemicals.
Abou El Naga RN; Azab SS; El-Demerdash E; Shaarawy S; El-Merzabani M; Ammar el-SM
Life Sci; 2013 Mar; 92(10):555-61. PubMed ID: 23352978
[TBL] [Abstract][Full Text] [Related]
23. Genistein sensitizes human hepatocellular carcinoma cells to TRAIL-mediated apoptosis by enhancing Bid cleavage.
Jin CY; Park C; Moon SK; Kim GY; Kwon TK; Lee SJ; Kim WJ; Choi YH
Anticancer Drugs; 2009 Sep; 20(8):713-22. PubMed ID: 19617819
[TBL] [Abstract][Full Text] [Related]
24. Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3.
Chen KF; Chen HL; Liu CY; Tai WT; Ichikawa K; Chen PJ; Cheng AL
Biochem Pharmacol; 2012 Mar; 83(6):769-77. PubMed ID: 22230479
[TBL] [Abstract][Full Text] [Related]
25. Catalytically active Yersinia outer protein P induces cleavage of RIP and caspase-8 at the level of the DISC independently of death receptors in dendritic cells.
Gröbner S; Adkins I; Schulz S; Richter K; Borgmann S; Wesselborg S; Ruckdeschel K; Micheau O; Autenrieth IB
Apoptosis; 2007 Oct; 12(10):1813-25. PubMed ID: 17624595
[TBL] [Abstract][Full Text] [Related]
26. Differential responsiveness of human hepatoma cells versus normal hepatocytes to TRAIL in combination with either histone deacetylase inhibitors or conventional cytostatics.
Dzieran J; Beck JF; Sonnemann J
Cancer Sci; 2008 Aug; 99(8):1685-92. PubMed ID: 18754884
[TBL] [Abstract][Full Text] [Related]
27. The role of oxidative stress in apoptosis induced by the histone deacetylase inhibitor suberoylanilide hydroxamic acid in human colon adenocarcinoma HT-29 cells.
Portanova P; Russo T; Pellerito O; Calvaruso G; Giuliano M; Vento R; Tesoriere G
Int J Oncol; 2008 Aug; 33(2):325-31. PubMed ID: 18636153
[TBL] [Abstract][Full Text] [Related]
28. Over-expression of Reticulon 3 (RTN3) enhances TRAIL-mediated apoptosis via up-regulation of death receptor 5 (DR5) and down-regulation of c-FLIP.
Lee JT; Lee TJ; Kim CH; Kim NS; Kwon TK
Cancer Lett; 2009 Jul; 279(2):185-92. PubMed ID: 19250737
[TBL] [Abstract][Full Text] [Related]
29. Cisplatin sensitizes human hepatocellular carcinoma cells, but not hepatocytes and mesenchymal stem cells, to TRAIL within a therapeutic window partially depending on the upregulation of DR5.
Zhang B; Shan H; Li D; Li ZR; Zhu KS; Jiang ZB; Huang MS
Oncol Rep; 2011 Feb; 25(2):461-8. PubMed ID: 21152876
[TBL] [Abstract][Full Text] [Related]
30. Bid sensitizes apoptosis induced by chemotherapeutic drugs in hepatocellular carcinoma.
Miao J; Chen GG; Chun SY; Chak EC; Lai PB
Int J Oncol; 2004 Sep; 25(3):651-9. PubMed ID: 15289866
[TBL] [Abstract][Full Text] [Related]
31. Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo.
Luong QT; O'Kelly J; Braunstein GD; Hershman JM; Koeffler HP
Clin Cancer Res; 2006 Sep; 12(18):5570-7. PubMed ID: 17000694
[TBL] [Abstract][Full Text] [Related]
32. Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells.
Sonnemann J; Kumar KS; Heesch S; Müller C; Hartwig C; Maass M; Bader P; Beck JF
Int J Oncol; 2006 Mar; 28(3):755-66. PubMed ID: 16465382
[TBL] [Abstract][Full Text] [Related]
33. Cyclooxygenase-2 inhibitor and interferon-beta synergistically induce apoptosis in human hepatoma cells in vitro and in vivo.
Nakamoto N; Higuchi H; Kanamori H; Kurita S; Tada S; Takaishi H; Toda K; Yamada T; Kumagai N; Saito H; Hibi T
Int J Oncol; 2006 Sep; 29(3):625-35. PubMed ID: 16865278
[TBL] [Abstract][Full Text] [Related]
34. Downregulation of survivin and activation of caspase-3 through the PI3K/Akt pathway in ursolic acid-induced HepG2 cell apoptosis.
Tang C; Lu YH; Xie JH; Wang F; Zou JN; Yang JS; Xing YY; Xi T
Anticancer Drugs; 2009 Apr; 20(4):249-58. PubMed ID: 19174695
[TBL] [Abstract][Full Text] [Related]
35. Perifosine synergistically enhances TRAIL-induced myeloma cell apoptosis via up-regulation of death receptors.
David E; Sinha R; Chen J; Sun SY; Kaufman JL; Lonial S
Clin Cancer Res; 2008 Aug; 14(16):5090-8. PubMed ID: 18698026
[TBL] [Abstract][Full Text] [Related]
36. [Relationship between death receptor 5 and apoptosis in hepatocellular carcinoma].
Zhu RX; Lin JS; Song YH; Li PY; Tao LW
Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):261-4. PubMed ID: 16875623
[TBL] [Abstract][Full Text] [Related]
37. SAHA/TRAIL combination induces detachment and anoikis of MDA-MB231 and MCF-7 breast cancer cells.
Lauricella M; Ciraolo A; Carlisi D; Vento R; Tesoriere G
Biochimie; 2012 Feb; 94(2):287-99. PubMed ID: 21835222
[TBL] [Abstract][Full Text] [Related]
38. Expression of anti-apoptotic factors modulates Apo2L/TRAIL resistance in colon carcinoma cells.
Lippa MS; Strockbine LD; Le TT; Branstetter DG; Strathdee CA; Holland PM
Apoptosis; 2007 Aug; 12(8):1465-78. PubMed ID: 17440816
[TBL] [Abstract][Full Text] [Related]
39. Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response.
Lagneaux L; Gillet N; Stamatopoulos B; Delforge A; Dejeneffe M; Massy M; Meuleman N; Kentos A; Martiat P; Willems L; Bron D
Exp Hematol; 2007 Oct; 35(10):1527-37. PubMed ID: 17697742
[TBL] [Abstract][Full Text] [Related]
40. Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma.
Chen MC; Huang HH; Lai CY; Lin YJ; Liou JP; Lai MJ; Li YH; Teng CM; Yang CR
Oncotarget; 2016 Jan; 7(1):402-17. PubMed ID: 26587975
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]